-
Bond Announces Conversion of Outstanding Debt into Equity at Significant Premium to Market
June 16, 2026 08:07 ET | Source: Our Bond, Inc. Major Investor Exchanges Approximately $3.3 Million of Debt for Convertible Preferred Equity Priced at $2.0265 Per Common Share — a Premium of More Than 200% to Recent Trading Levels Above-Market Conversion Along With Separate Payment Schedule Adjustment Reduce 2026 Debt Burden By $4.3M, Reflecting Investors’…
-
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score – WALTHAM, Mass., June 14, 2026 (GLOBE…
-
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas June 07, 2026 19:41 ET | Source: GNI Group Co., Ltd. TOKYO, June 07, 2026 (GLOBE NEWSWIRE) — GNI Group Co., Ltd. (TSE: 2160) today announced that it has entered into an agreement to acquire 100% of the shares…
-
SMT Celebrates 20 Years of the Cocoon Occluder Journey, Transforming Lives in Congenital and Structural Heart Defects
Mumbai, Maharashtra, India Congenital Heart Disease (CHD) is one of the most common birth defects, affecting approximately 1% of live births globally and accounting for more than 4.18 million cases in children under five1. Despite advances in medical care, CHD continues to be a leading cause of infant and child mortality, highlighting the need for…
-
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
June 05, 2026 20:13 ET | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash,…
-
Morepen Bags Rs. 825 Crore Global Deal
Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs. 825 crore (USD 91 million) from a leading global pharma major. Morepen Bags Rs. 825 Crore Global Deal, Expands into High-Growth CDMO Segment Supplies under the mandate are expected to commence within the…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
